🇺🇸 FDA
Patent

US 8399412

Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions

granted A61KA61K38/08A61K38/2292

Quick answer

US patent 8399412 (Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions) held by REGENERX BIOPHARMACEUTICALS, INC. expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERX BIOPHARMACEUTICALS, INC.
Grant date
Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/08, A61K38/2292, A61K8/64, A61P